Preliminary data from the first-in-human study presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated that CS5001 is well-tolerated and exhibits encouraging ...

PHILADELPHIA, PA, USA I 09, 2024 I GSK plc (LSE/NYSE: GSK) today announced statistically significant and clinically meaningful overall survival (OS) ...

▎药明康德内容团队编辑  肿瘤免疫微环境复杂多变，其中的免疫激活细胞和免疫抑制细胞双方持续交战，免疫激活细胞CD8+ T因此逐渐耗竭。调节性T细胞（Treg）、MDSC（髓系来源的抑制细胞）等免疫抑制细胞数量众多、手段多样，是压制CD8+ T细胞杀伤肿瘤的重要力量，往往会阻碍免疫治疗的效果。因此，常规的肿瘤蛋白药物或 ...

US FDA grants breakthrough therapy designation to datopotamab deruxtecan for patients with previously treated advanced EGFR-mutated NSCLC: Cambridge, UK Tuesday, December 10, 2024 ...